Tumor-suppressor pseudogene RRN3P3 upregulated the expression of EZH2 by competitively binding hsa-miR-26a-5p and hsa-miR-26b-5p, which explained the higher expression of EZH2 in the low-risk subtype (Figure 4A, right panel). The gene discussed is EZH2; the disease is neoplasm.